Full-Text Search:
Home|About CNKI|User Service|中文
Add to Favorite Get Latest Update

A New Hope for Asthma Treatment——Evaluation of Progress Made in the Study of Leukotriene Antagonists

The Leukotrienes(LTs) which are formed from araehidonic acid via 5-lipoxygenase pathways are important inflammatory mediators in the treatment of asthma.LTs are mainly classified as di-hydroxy-LTs(LT B_4) and cysteinyl-LTs and take effect when they bind to specific receptors in the airway.They play an important role in the treatment of asthma,so LTs receptor antagonists and synthesis inhibitors can be effective in treating prophylaxsis and asthma. LTs antagonists showing anti-asthma and anti- inflammation results,have been included in the latest U.S.Asthma Guidelines and will become a new, promising class of drugs in the treatment of asthma. Zileuton(Zyflo),ibudilast,pranlukast,and Zafir- lukast(Accolate) have been launched in several countries,and Montelukast(singulair) is nearing market introduction,while more than 10 others are being studied and are in the second and third phase of clinical trials,but none have been launched in China.
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
©CNKI All Rights Reserved